ORKA

Oruka Therapeutics Inc

• TipRanks·1d ago

  ORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for Investors

• TipRanks·10/02 10:25

  BTIG Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)

• TipRanks·09/24 16:31

  ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors

• Dow Jones·09/24 12:50

  Oruka Therapeutics Price Target Maintained With a $165.00/Share by Wedbush

• Benzinga·09/24 12:40

  Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $165 Price Target

• TipRanks·09/24 12:30

  Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Co-Diagnostics (CODX)

• Dow Jones·09/24 11:42

  Oruka Therapeutics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

• TipRanks·09/24 10:30

  Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Oruka Therapeutics (ORKA) and Harmony Biosciences Holdings (HRMY)

• TipRanks·09/23 17:30

  Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

• Seeking Alpha·09/23 17:19

  Oruka falls after updating mid-stage trial data for plaque psoriasis therapy

• Benzinga·09/23 13:49

  Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy

• TipRanks·09/23 13:35

  Oruka Therapeutics ORKA-001 data meet base case, says Clear Street

• NASDAQ·09/23 12:07

  Oruka Reports Positive Week 28 Results For ORKA-001 In Plaque Psoriasis; Stock Down

• TipRanks·09/23 11:11

  Oruka Therapeutics announces Week 28 results for ORKA-001

• Benzinga·09/23 11:08

  Oruka Therapeutics Announces Week 28 Results From Its EVERLAST-A Phase 2A Trial Of ORKA-001 In Moderate-To-Severe Plaque Psoriasis; ORKA-001 Maintained Favorable Safety And Tolerability Profile Through Week 28; 16-Week EVERLAST-B Data Expected In Q4 2026